SCHEMBL842763

SCHEMBL842763

CCNc1nc2c(Oc3ccccc3)nc(C)c(C)c2n1CC(C)C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
TLR7 Q9NYK1 1/20 0.32
MAPT P10636 2/20 0.32
KDM4E B2RXH2 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE1C Q14123 1/20 0.31
LMNA P02545 2/20 0.31
HTT P42858 2/20 0.31
NPC1 O15118 1/20 0.31
GLA P06280 1/20 0.31
GAA P10253 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL842385 0.81 RPS6KA5 (0.34) MEN1KMT2AALDH1A1SMN1; SMN2TLR7
SCHEMBL5124491 0.80 MEN1 (0.33) MEN1KMT2AALDH1A1SMN1; SMN2TLR7
SCHEMBL842373 0.75 TLR7 (0.33) TLR7
SCHEMBL4792276 0.72 LMNA (0.35) MEN1KMT2AALDH1A1SMN1; SMN2TLR7
SCHEMBL4793644 0.70 ALDH1A1 (0.35) MEN1KMT2AALDH1A1CYP1A2CYP2C9
SCHEMBL4792944 0.69 HPGD (0.40) KMT2AALDH1A1SMN1; SMN2TLR7MAPT
SCHEMBL863141 0.68 TLR7 (0.56) TLR7LMNA
SCHEMBL4792366 0.68 HPGD (0.39) MEN1KMT2ASMN1; SMN2TLR7MAPT
SCHEMBL4875215 0.68 TLR7 (0.39) SMN1; SMN2TLR7MAPTLMNARPS6KA5
SCHEMBL4794750 0.67 HPGD (0.39) MEN1KMT2ASMN1; SMN2TLR7MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143270-B2 2-amino 1H-in-imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-03-27 US disclosed
EP-1784180-A4 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2009-07-22 EP disclosed
US-20090023720-A1 2-Amino 1H-Imidazo Ring Systems and Methods 3M INNOVATIVE PROPERTIES COMPANY 2009-01-22 US disclosed
EP-1784180-A2 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-16 EP disclosed
WO-2006029115-A2 2-AMINO 1H IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-03-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023720-A1 2-Amino 1H-Imidazo Ring Systems and Methods IL2, IL2RA, IL4I1 MEN1 3048/4885KMT2A 1860/4885ALDH1A1 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.